Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older

被引:535
作者
Meijer, Chris J. L. M. [1 ]
Berkhof, Johannes [2 ]
Castle, Philip E. [3 ]
Hesselink, Albertus T. [1 ]
Franco, Eduardo L. [4 ]
Ronco, Guglielmo [5 ]
Arbyn, Marc [6 ,7 ]
Bosch, F. Xavier [8 ]
Cuzick, Jack [9 ,11 ]
Dillner, Joakim [10 ]
Heideman, Danielle A. M. [1 ]
Snijders, Peter J. F. [1 ]
机构
[1] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1007 MB Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Dept Clin Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands
[3] NIH, Dept Canc Epidemiol & Genet, Washington, DC USA
[4] McGill Univ, Div Canc Epidemiol, Montreal, PQ, Canada
[5] Ctr Prevenz Oncol, Canc Epidemiol Unit, Turin, Italy
[6] Sci Inst Publ Hlth, Canc Epidemiol Unit, Brussels, Belgium
[7] IARC, ECCG European Cooperat Dev & Implementat Canc Scr, Lyon, France
[8] Hosp Ilobregat, ICO, Serv Epidemiol, Barcelona, Spain
[9] Barts & London Queen Marys Sch Med & Dent, London, England
[10] Lund Univ, Univ Hosp, Dept Med Microbiol, Malmo, Sweden
[11] Canc Res UK, London, England
关键词
HPV-DNA testing; cervical screening; HPV test guidelines; HPV test requirements; HPV test statistics; POLYMERASE-CHAIN-REACTION; RISK HUMAN-PAPILLOMAVIRUS; LIQUID-BASED CYTOLOGY; BASE-LINE; HYBRID-CAPTURE-2; RECRUITMENT; NEOPLASIA; MANAGEMENT; GRADE-3;
D O I
10.1002/ijc.24010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Given the strong etiologic link between high-risk HPV infection and cervical cancer high-risk HPV testing is now being considered as an alternative for cytology-based cervical cancer screening. Many test systems have been developed that can detect the broad spectrum of hrHPV types in one assay. However, for screening purposes the detection of high-risk HPV is not inherently useful unless it is informative for the presence of high-grade cervical intraepithelial neoplasia (CIN 2/3) or cancer. Candidate high-risk HPV tests to be used for screening should reach an optimal balance between clinical sensitivity and specificity for detection of high-grade CIN and cervical cancer to minimize redundant or excessive follow-up procedures for high-risk HPV positive women without cervical lesions. Data from various large screening studies have shown that high-risk HPV testing by hybrid capture 2 and GP5+/6+-PCR yields considerably better results in the detection of CIN 2/3 than cytology. The data from these studies can be used to guide the translation of high-risk HPV testing into clinical practice by setting standards of test performance and characteristics. On the basis of these data we have developed guidelines for high-risk HPV test requirements for primary cervical screening and validation guidelines for candidate HPV assays. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:516 / 520
页数:5
相关论文
共 34 条
[11]  
Dillner Lena, 2008, Central European Journal of Public Health, V16, pS18
[12]  
Gravitt PE, 2003, CANCER EPIDEM BIOMAR, V12, P477
[13]   Why CIN3 and CIN2 should be distinguished on histological reports [J].
Herbert, A. ;
Arbyn, M. ;
Bergeron, C. .
CYTOPATHOLOGY, 2008, 19 (01) :63-64
[14]   Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia [J].
Hesselink, A. T. ;
van Ham, M. A. P. C. ;
Heideman, D. A. M. ;
Groothuismink, Z. M. A. ;
Rozendaal, L. ;
Berkhof, J. ;
van Kemenade, F. J. ;
Massuger, L. A. F. G. ;
Melchers, W. J. G. ;
Meijer, C. J. L. M. ;
Snijders, P. J. F. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (10) :3215-3221
[15]   Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+PCR method in a population-based cervical screening program [J].
Hesselink, A. T. ;
Bulkmans, N. W. J. ;
Berkhof, J. ;
Lorincz, A. T. ;
Meijer, C. J. L. M. ;
Snijders, P. J. F. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (10) :3680-3685
[16]   Comparison of hybrid capture 2 with in situ hybridization for the detection of high-risk human papillomavirus in liquid-based cervical samples [J].
Hesselink, AT ;
van den Brule, AJC ;
Brink, AATP ;
Berkhof, J ;
van Kemenade, FJ ;
Verheijen, RHM ;
Snijders, PJF .
CANCER CYTOPATHOLOGY, 2004, 102 (01) :11-18
[17]  
International Agency for Research on Cancer, 2007, IARC MON EV CARC RIS, V90
[18]   Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison [J].
Jacobs, MV ;
Snijders, PJF ;
Voorhorst, FJ ;
Dillner, J ;
Forslund, O ;
Johansson, B ;
Doeberitz, MVK ;
Meijer, CJLM ;
Meyer, T ;
Nindl, I ;
Pfister, H ;
Stockfleth, E ;
Strand, A ;
Wadell, G ;
Walboomers, JMM .
JOURNAL OF CLINICAL PATHOLOGY, 1999, 52 (07) :498-503
[19]   Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer [J].
Mayrand, Marie-Helene ;
Duarte-Franco, Eliane ;
Rodrigues, Isabel ;
Walter, Stephen D. ;
Hanley, James ;
Ferenczy, Alex ;
Ratnam, Sam ;
Coutle, Francois ;
Franco, Eduardo L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (16) :1579-1588
[20]   Against which human papillomavirus types shall we vaccinate and screen?: The international perspective [J].
Muñoz, N ;
Bosch, FX ;
Castellsagué, X ;
Díaz, M ;
De Sanjose, S ;
Hammouda, D ;
Shah, KV ;
Meijer, CJLM .
INTERNATIONAL JOURNAL OF CANCER, 2004, 111 (02) :278-285